2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3416 Clinical pharmacokinetics and exposure–response analysis to support recommended dose of pivekimab sunirine in patients with blastic plasmacytoid dendritic cell neoplasm

Gaurav Bedse, PhD, Shaun Kumar2, Daniel Parra Gonzalez3, Jalaja Potluri, MD4, Rajeev Menon, PhD5, Benjamin Engelhardt6, Jiuhong Zha, PhD7
1 AbbVie Inc, North Chicago, Illinois, United States
2 Parexel International, Raleigh, United States
3 Parexel International, Raleigh, United States
4 AbbVie Inc, North Chicago, Illinois, United States
5 AbbVie Inc, North Chicago, Illinois, United States
6 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany
7 AbbVie Inc, North Chicago, Illinois, United States

Introduction: Pivekimab sunirine (PVEK) is a CD123-targeted antibody-drug conjugate (ADC) comprised of an anti-CD123 monoclonal immunoglobulin G1 (IgG1) antibody conjugated via a cleavable linker to an indolinobenzodiazepine pseudodimer (IGN) payload FGN849. IGN induces single-strand DNA breaks through alkylation, which induces cell death. PVEK is the first-in-class and only ADC FDA-approved for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and can be initiated in an outpatient setting.  Here, we present the clinical pharmacokinetics and exposure-response (E-R) relationships for PVEK monotherapy that supported the recommended PVEK selection of 0.045 mg/kg administered every 3 weeks (Q3W).

Methods: PVEK was administered intravenously in the CADENZA trial (NCT03386513) across two schedules: 0.015–0.45 mg/kg Q3W and fractionated dosing (0.015–0.06 mg/kg) on Days 1, 4, and 8 Q3W. Dose escalation and expansion cohorts mainly included CD123-positive patients with relapsed/refractory (R/R) AML and R/R or frontline BPDCN. Pharmacokinetic (PK) data were analyzed by non-compartmental analysis (Phoenix® WinNonlin® 8.3) and modeled by an integrated population PK (pop-PK) model for PVEK (ADC), total antibody (TAb), and payload (NONMEM 7.4.4). Exposure metrics derived from the pop-PK model (Cycle 1 maximum concentration [Cmax,C1], Cycle 1 average concentration [Cavg,C1], and Cavg up to the time of event [Cavg,TE]) for PVEK (ADC) and unconjugated payload FGN849 were examined using exposure-quartile plots and logistic regression analyses. Key efficacy and safety endpoints examined in E-R analyses were composite complete remission (complete response [CR]+ clinical complete response [CRc]), Grade ≥2 infusion-related reactions (IRR), and Grade ≥3 infections.

Results: PVEK (ADC) and total antibody (TAb) exhibited greater-than-dose-proportional PK in the lower dose range of 0.045–0.18 mg/kg Q3W, including the recommended dose, consistent with target-mediated drug disposition. Dose-proportional PK was observed at higher doses (0.18–0.45 mg/kg Q3W). ADC and FGN849 exposures were comparable between CD123-positive AML and BPDCN patients at 0.045 mg/kg Q3W. The pop-PK model adequately characterized CADENZA PK data (N=175), with an estimated ADC clearance of 1.78 L/h (between-subject variability: 84%).

Exposure-efficacy analyses demonstrated that frontline BPDCN patients achieving CR+CRc had a higher median PVEK Cavg,C1 and Cmax,C1 than those who did not (N=33). A consistent trend of higher ADC exposures (Cavg,C1) was also observed in R/R BPDCN patients (N= 50) who achieved CR+ CRc versus those who did not. Exposure-safety analyses on data from all patients in CADENZA across doses of 0.015–0.45 mg/kg (N=176) identified significant positive associations between FGN849 exposure and both Grade ≥2 IRR and Grade ≥3 infections, informing the benefit-risk profile at the recommended dose.

Conclusions: Integrated clinical PK and E-R analyses from the CADENZA trial support 0.045 mg/kg Q3W as the recommended dose for PVEK monotherapy in adult BPDCN patients, balancing meaningful clinical efficacy and an acceptable safety profile.

Gaurav Bedse, PhD: AbbVie Inc - Current equity holder in publicly-traded company; AbbVie Inc - Divested equity in a private or publicly-traded company in the past 24 months; AbbVie Inc - Current Employment